RU2434019C3 - Ацилированные glp-1 соединения - Google Patents

Ацилированные glp-1 соединения

Info

Publication number
RU2434019C3
RU2434019C3 RU2007134156A RU2007134156A RU2434019C3 RU 2434019 C3 RU2434019 C3 RU 2434019C3 RU 2007134156 A RU2007134156 A RU 2007134156A RU 2007134156 A RU2007134156 A RU 2007134156A RU 2434019 C3 RU2434019 C3 RU 2434019C3
Authority
RU
Russia
Prior art keywords
compounds
glp
ethoxy
acylated glp
activity
Prior art date
Application number
RU2007134156A
Other languages
English (en)
Russian (ru)
Other versions
RU2007134156A (ru
RU2434019C2 (ru
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36821525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2434019(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2007134156A publication Critical patent/RU2007134156A/ru
Publication of RU2434019C2 publication Critical patent/RU2434019C2/ru
Application granted granted Critical
Publication of RU2434019C3 publication Critical patent/RU2434019C3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
RU2007134156A 2005-03-18 2006-03-20 Ацилированные glp-1 соединения RU2434019C3 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102171 2005-03-18
EP05102171.5 2005-03-18

Publications (3)

Publication Number Publication Date
RU2007134156A RU2007134156A (ru) 2009-04-27
RU2434019C2 RU2434019C2 (ru) 2011-11-20
RU2434019C3 true RU2434019C3 (ru) 2020-07-20

Family

ID=36821525

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007134156A RU2434019C3 (ru) 2005-03-18 2006-03-20 Ацилированные glp-1 соединения

Country Status (23)

Country Link
US (2) US8129343B2 (cg-RX-API-DMAC7.html)
EP (2) EP1863839B1 (cg-RX-API-DMAC7.html)
JP (3) JP5209463B2 (cg-RX-API-DMAC7.html)
KR (1) KR101205272B1 (cg-RX-API-DMAC7.html)
CN (3) CN104402989A (cg-RX-API-DMAC7.html)
AT (1) ATE476446T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006224536B9 (cg-RX-API-DMAC7.html)
BR (2) BR122019002626A2 (cg-RX-API-DMAC7.html)
CA (1) CA2601784C (cg-RX-API-DMAC7.html)
DE (1) DE602006015928D1 (cg-RX-API-DMAC7.html)
DK (2) DK1863839T3 (cg-RX-API-DMAC7.html)
ES (2) ES2350051T3 (cg-RX-API-DMAC7.html)
HU (2) HUE028194T2 (cg-RX-API-DMAC7.html)
IL (1) IL184051A (cg-RX-API-DMAC7.html)
MX (1) MX2007011220A (cg-RX-API-DMAC7.html)
NL (1) NL300936I2 (cg-RX-API-DMAC7.html)
NO (2) NO337946B1 (cg-RX-API-DMAC7.html)
PL (2) PL2322546T3 (cg-RX-API-DMAC7.html)
PT (2) PT2322546E (cg-RX-API-DMAC7.html)
RU (1) RU2434019C3 (cg-RX-API-DMAC7.html)
TW (2) TWI362392B (cg-RX-API-DMAC7.html)
WO (1) WO2006097537A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200707261B (cg-RX-API-DMAC7.html)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
JP4949838B2 (ja) * 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR20070120112A (ko) * 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN101842386A (zh) * 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
CN107412742B (zh) 2007-11-16 2022-03-15 诺沃—诺迪斯克有限公司 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
ES2611007T3 (es) 2008-03-18 2017-05-04 Novo Nordisk A/S Análogos de insulina acilada, estabilizados frente a proteasas
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
TW200950799A (en) 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
EP2323694A1 (en) 2008-08-06 2011-05-25 Novo Nordisk Health Care AG Conjugated proteins with prolonged in vivo efficacy
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
TWI504405B (zh) 2009-01-22 2015-10-21 Novo Nordisk Healthcare Ag 穩定的生長激素化合物
KR20110117666A (ko) 2009-01-23 2011-10-27 노보 노르디스크 에이/에스 알부민 바인더 ａ-ｂ-ｃ-ｄ-ｅ-를 갖는 ｆｇｆ21 유도체 및 그것의 사용
EP2440235A1 (en) * 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
CN102791731B (zh) * 2009-12-16 2016-04-20 诺沃—诺迪斯克有限公司 Glp-1类似物和衍生物
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
CN102186881B (zh) * 2010-04-27 2015-04-08 贝达药业股份有限公司 胰高血糖素样肽-1衍生物及其应用
CA2797431C (en) * 2010-04-27 2016-06-21 Zhejiang Beta Pharma Inc. Glucagon-like peptide-1 analogue and use thereof
CN103124739B (zh) * 2010-05-17 2015-11-25 贝达药业股份有限公司 一种新胰高血糖素样肽类似物、组合物及其用途
WO2012016419A1 (zh) * 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
WO2012062804A1 (en) 2010-11-09 2012-05-18 Novo Nordisk A/S Double-acylated glp-1 derivatives with a linker
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
JP2014502985A (ja) 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス Ｇｌｐ−１粒子および組成物
CN103298457A (zh) 2011-01-19 2013-09-11 诺沃—诺迪斯克有限公司 Glp-1组合物
JP2014510739A (ja) * 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
KR101496136B1 (ko) * 2011-03-30 2015-02-26 베타 파머수티컬 컴퍼니 리미티드 글루카곤 유사 펩타이드-1 유사체 및 이의 용도
MY161450A (en) * 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
KR102093463B1 (ko) * 2011-04-12 2020-03-26 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
EP2720699B1 (en) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
CA2842323A1 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
RU2643515C2 (ru) 2011-12-29 2018-02-02 Ново Нордиск А/С Дипептид, содержащий непротеиногенную аминокислоту
WO2013120554A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
WO2013120553A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
KR102266299B1 (ko) * 2012-03-22 2021-06-18 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
ES2629735T3 (es) * 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
CN107739409A (zh) 2012-05-18 2018-02-27 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
JP6059802B2 (ja) 2012-07-01 2017-01-11 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用
ES2620111T3 (es) 2012-07-23 2017-06-27 Zealand Pharma A/S Análogos de glucagón
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2908844A1 (en) 2012-10-17 2015-08-26 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PL2991671T3 (pl) 2013-05-02 2019-01-31 Novo Nordisk As Doustne dawkowanie związków glp-1
ES2646538T3 (es) * 2013-06-20 2017-12-14 Novo Nordisk A/S Derivados de GLP-1 y sus usos
BR112015032875A2 (pt) 2013-07-04 2017-11-07 Novo Nordisk As derivados de peptídeos do tipo glp-1, e usos dos mesmos
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345569B2 (en) * 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
CA2932477C (en) 2013-12-06 2023-10-10 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US9963496B2 (en) 2014-02-18 2018-05-08 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
PL3139948T3 (pl) 2014-05-07 2020-08-10 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
CN113214397A (zh) 2014-07-17 2021-08-06 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
PL3189072T3 (pl) 2014-09-05 2019-04-30 Univ Copenhagen Analogi peptydowe gip
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
MX381640B (es) 2014-10-29 2025-03-04 Zealand Pharma As Metodos y compuestos agonistas de gip.
ES2739289T3 (es) 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
AU2015371056B2 (en) 2014-12-23 2020-06-25 Novo Nordisk A/S FGF21 derivatives and uses thereof
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN107205949A (zh) * 2015-01-29 2017-09-26 诺和诺德股份有限公司 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
ES2763329T3 (es) 2015-04-16 2020-05-28 Zealand Pharma As Análogo de glucagón acilado
AU2016280873A1 (en) * 2015-06-16 2018-01-04 Sun Pharma Advanced Research Company Limited Long acting liraglutide compositions
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
CN106554403B (zh) * 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
CN106554409B (zh) * 2015-09-30 2020-04-07 天津药物研究院有限公司 一种长效胰高血糖素样肽-1类似物及其应用
CN106554408A (zh) * 2015-09-30 2017-04-05 天津药物研究院有限公司 长效胰高血糖素样肽-1类似物二聚体及其应用
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
CN106928343A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 索玛鲁肽的制备方法
ES2835033T3 (es) 2016-03-03 2021-06-21 Novo Nordisk As Derivados de GLP-1 y sus usos
CN107266557B (zh) * 2016-04-06 2020-04-07 天津药物研究院有限公司 一种聚乙二醇修饰的胰高血糖素样肽-1类似物
RU2768283C2 (ru) * 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
WO2018078112A1 (en) 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
CN109922835B (zh) 2016-11-07 2023-08-04 诺和诺德股份有限公司 Peg化合物的dchbs活性酯及其用途
DK3821905T3 (da) 2016-12-16 2022-11-14 Novo Nordisk As Insulin indeholdende farmaceutiske sammensætninger
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
KR20190126335A (ko) * 2017-03-08 2019-11-11 인타르시아 세라퓨틱스 인코포레이티드 약물 전달 장치로부터 메스꺼움 유발 화합물을 투여하기 위한 장치 및 방법
EP4361173A3 (en) 2017-05-31 2024-07-03 University of Copenhagen Long-acting gip peptide analogues
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
AU2018303625A1 (en) * 2017-07-19 2020-02-06 Novo Nordisk A/S Bifunctional compounds
TWI847306B (zh) * 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
WO2019066609A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
BR112020006246A2 (pt) * 2017-10-12 2021-03-30 Novo Nordisk A/S Método para controle do peso de um sujeito em necessidade
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
WO2019120639A1 (en) 2017-12-21 2019-06-27 Bachem Holding Ag Solid phase synthesis of acylated peptides
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN110294800B (zh) * 2018-03-22 2022-03-04 齐鲁制药有限公司 一种索玛鲁肽的制备方法
EP3774902A1 (en) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
HUE067499T2 (hu) 2018-04-05 2024-10-28 Sun Pharmaceutical Ind Ltd Új GLP-1 analógok
EP3773475A1 (en) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
CN115814063A (zh) * 2018-04-19 2023-03-21 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
MX2020011427A (es) 2018-05-04 2020-12-07 Novo Nordisk As Derivados del polipeptido insulinotropico dependiente de la glucosa (gip) y usos de estos.
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
HRP20230929T1 (hr) 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
CN109180801B (zh) * 2018-11-01 2021-08-13 汉肽生物医药集团有限公司 一种合成索玛鲁肽的方法
AU2019391300B2 (en) 2018-12-03 2025-06-26 Antag Therapeutics Aps Modified GIP peptide analogues
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
ES2994462T3 (en) 2018-12-21 2025-01-24 Novo Nordisk As Process of spray drying of glp-1 peptide
CN113329810A (zh) 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
EP3927815A2 (en) 2019-02-20 2021-12-29 Novo Nordisk A/S Aminoacyl-trna synthetases and uses hereof
WO2020190757A1 (en) 2019-03-15 2020-09-24 Novetide Ltd. Improved processes for the preparation of semaglutide
CN113631251B (zh) * 2019-03-15 2025-04-25 诺和诺德股份有限公司 Glp-1肽的喷雾干燥工艺
CN111748019A (zh) * 2019-03-29 2020-10-09 深圳翰宇药业股份有限公司 一种多肽衍生化合物的合成方法
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation
BR112021020071A2 (pt) * 2019-04-11 2021-12-14 Jiangsu Hansoh Pharmaceutical Group Co Ltd Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
CA3139613A1 (en) * 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
EP4025192B1 (en) 2019-09-02 2025-12-03 Novo Nordisk A/S Process for producing a tablet comprising glp-1 peptides
US20230192799A1 (en) * 2019-09-16 2023-06-22 Biomarin Pharmaceutical Inc. CNP Variants and Conjugates Thereof
CN110590934B (zh) * 2019-09-25 2020-12-08 北京乐普医药科技有限公司 一种glp-1化合物
AU2020377469A1 (en) 2019-11-06 2022-04-28 Novo Nordisk A/S GLP-1 receptor agonists in dementia
EP3819308A1 (en) 2019-11-07 2021-05-12 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of derivatized amino acids
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
MX2022008139A (es) * 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Compuestos de glp-1 de acción prolongada.
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
KR102375262B1 (ko) 2020-02-14 2022-03-16 주식회사 지투지바이오 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
US20230295077A1 (en) 2020-04-10 2023-09-21 Fresenius Kabi Oncology Limited An improved process for the preparation of semaglutide side chain
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
AR122579A1 (es) * 2020-06-12 2022-09-21 Lilly Co Eli Proceso para preparar un agonista dual glp-1 / glucagón
TW202214679A (zh) 2020-07-22 2022-04-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及gip受體共促效劑
TW202220973A (zh) 2020-08-06 2022-06-01 美商迦舒布魯姆生物有限公司 雜環glp-1促效劑
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
JP2023541827A (ja) 2020-09-07 2023-10-04 サイプルメド ゲーエムベーハー Ｇｌｐ－１受容体アゴニストの改善された医薬製剤
WO2022068920A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
EP4240420A1 (en) 2020-11-06 2023-09-13 Novo Nordisk A/S Glp-1 prodrugs and uses hereof
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
KR20230160369A (ko) 2021-03-25 2023-11-23 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. Gip 및 glp-1의 이중 수용체 작용제, 약물 조성물 및 용도
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
WO2022258805A1 (en) 2021-06-10 2022-12-15 Antag Therapeutics Aps Treatment of obesity and obesity-related disorders
AU2022298186B2 (en) 2021-06-23 2024-10-03 Peptron, Inc. Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
WO2022268214A1 (zh) 2021-06-25 2022-12-29 甘李药业股份有限公司 Pcsk9抑制剂和glp-1受体激动剂的药物组合
US20250276043A1 (en) * 2021-06-25 2025-09-04 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical Composition Containing GLP-1 Compound
WO2023285334A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
CN116635402B (zh) 2021-07-14 2024-03-15 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
JP2024525377A (ja) 2021-07-15 2024-07-12 ノヴォ ノルディスク アー／エス Ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む錠剤
CN116554299A (zh) * 2021-07-19 2023-08-08 青岛博睿精创科技有限公司 长效glp-1多肽类似物及其制备方法和应用
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions
TWI876242B (zh) 2021-12-13 2025-03-11 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
CN118973602A (zh) 2022-03-30 2024-11-15 诺和诺德股份有限公司 配制方法
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2023217744A1 (en) 2022-05-10 2023-11-16 Novo Nordisk A/S Prodrugs of glp-1 polypeptide and uses thereof
US20250195617A1 (en) 2022-05-23 2025-06-19 Ascendis Pharma Growth Disorders A/S Liquid Pharmaceutical Formulations of CNP Compounds
JP2025521774A (ja) 2022-07-05 2025-07-10 ジー２ジーバイオ インコーポレイテッド セマグルチドまたはその薬学的に許容可能な塩を含む徐放性微粒球製剤およびその製造方法
TW202421654A (zh) 2022-09-28 2024-06-01 丹麥商西蘭製藥公司 治療肥胖之方法
WO2024079043A1 (en) 2022-10-10 2024-04-18 Bachem Holding Ag Method of manufacturing a peptide with a lysine derivative
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
JP2025539630A (ja) 2022-12-16 2025-12-05 ペプトロン インコーポレイテッド Ｇｌｐ－１受容体アゴニストまたはその薬学的に許容可能な塩を含む徐放性微粒球およびその用途
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
EP4642440A1 (en) 2022-12-30 2025-11-05 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN120936383A (zh) 2023-03-06 2025-11-11 阿森迪斯药物股份有限公司 含白蛋白结合部分的药物的化合物
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
AU2024241939A1 (en) 2023-03-30 2025-10-02 Novo Nordisk A/S Fusion compounds and uses thereof
WO2024234320A1 (zh) * 2023-05-17 2024-11-21 南京知和医药科技有限公司 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2024256632A1 (en) 2023-06-15 2024-12-19 Novo Nordisk A/S Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025078040A1 (en) 2023-10-09 2025-04-17 Bachem Holding Ag Lysine salt and method of manufacturing a lysine derivative
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
WO2025106773A1 (en) 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
GB202403746D0 (en) 2024-03-15 2024-05-01 New Roger Randal Charles Formulations demonstrating an oral depot effect
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464022B1 (en) 1989-03-20 2000-05-31 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE69737479T4 (de) * 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0929576A1 (en) 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
CN100540566C (zh) 1998-12-07 2009-09-16 研究及应用科学协会股份有限公司 胰高血糖素样肽-1的类似物
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003519664A (ja) 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
JP2005530732A (ja) 2002-04-10 2005-10-13 イーライ・リリー・アンド・カンパニー 胃不全麻痺の治療
EP1594529B1 (en) 2003-02-19 2010-01-20 Ipsen Pharma Analogues of glp-1
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
WO2005014049A2 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
JP4949838B2 (ja) * 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
EP1704165B1 (en) 2003-12-18 2010-03-17 Novo Nordisk A/S Glp-1 compounds
AU2004298425A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 analogues linked to albumin-like agents
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
WO2006051110A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물

Also Published As

Publication number Publication date
TWI372629B (en) 2012-09-21
IL184051A (en) 2015-08-31
AU2006224536A1 (en) 2006-09-21
MX2007011220A (es) 2007-10-17
KR20070120089A (ko) 2007-12-21
JP2013063984A (ja) 2013-04-11
US8129343B2 (en) 2012-03-06
RU2007134156A (ru) 2009-04-27
US8536122B2 (en) 2013-09-17
TW200942255A (en) 2009-10-16
RU2434019C2 (ru) 2011-11-20
CN101133082A (zh) 2008-02-27
BRPI0607762A2 (pt) 2010-03-23
BRPI0607762B1 (pt) 2019-05-07
ES2350051T3 (es) 2011-01-17
JP4585037B2 (ja) 2010-11-24
JP2010116407A (ja) 2010-05-27
EP1863839A2 (en) 2007-12-12
TWI362392B (en) 2012-04-21
NL300936I2 (nl) 2018-08-07
PT2322546E (pt) 2016-01-22
NO2018023I1 (cg-RX-API-DMAC7.html) 2018-07-05
WO2006097537A2 (en) 2006-09-21
CN104017062A (zh) 2014-09-03
EP2322546A1 (en) 2011-05-18
US20120295847A1 (en) 2012-11-22
CA2601784A1 (en) 2006-09-21
DK1863839T3 (da) 2010-11-22
KR101205272B1 (ko) 2013-01-11
DK2322546T3 (en) 2015-12-14
WO2006097537A3 (en) 2007-01-25
ES2557313T3 (es) 2016-01-25
BR122019002626A2 (cg-RX-API-DMAC7.html) 2019-04-02
TW200700433A (en) 2007-01-01
CN101133082B (zh) 2016-01-13
HUS1800019I1 (hu) 2018-06-28
IL184051A0 (en) 2007-10-31
DE602006015928D1 (de) 2010-09-16
EP2322546B1 (en) 2015-09-30
NO337946B1 (no) 2016-07-18
CA2601784C (en) 2013-12-24
BRPI0607762B8 (pt) 2021-05-25
ZA200707261B (en) 2008-05-28
AU2006224536B9 (en) 2012-05-10
JP2008533105A (ja) 2008-08-21
NO20075342L (no) 2007-12-18
PT1863839E (pt) 2010-11-10
AU2006224536B2 (en) 2012-04-05
EP1863839B1 (en) 2010-08-04
PL1863839T3 (pl) 2011-01-31
CN104402989A (zh) 2015-03-11
JP5209463B2 (ja) 2013-06-12
HUE028194T2 (en) 2016-12-28
US20090156478A1 (en) 2009-06-18
ATE476446T1 (de) 2010-08-15
PL2322546T3 (pl) 2016-03-31

Similar Documents

Publication Publication Date Title
RU2434019C3 (ru) Ацилированные glp-1 соединения
RU2470016C2 (ru) Производное бипиразола
ES2705233T3 (es) Conjugados de ácidos grasos de quetiapina, proceso para su fabricación y usos
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
EA200400881A1 (ru) Азаарилпиперазины
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
RU2009141187A (ru) Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с
EA200500715A1 (ru) Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
ECSP044975A (es) Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, metodos de preparación y composiciones que los contienen
JP2005530732A5 (cg-RX-API-DMAC7.html)
CO5280073A1 (es) Composiciones
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
ITMI20020808A1 (it) Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
CR7938A (es) Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
AR031679A1 (es) Una composicion farmaceutica
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20200720